Progress in the Treatment of Ischemic Complications After Percutaneous Transluminal Coronary Angioplasty

Bao-qiao QI,Xiang-jun YANG

DOI: https://doi.org/10.3969/j.issn.1004-3934.2006.04.018

2006-01-01

Abstract:The ischemic complications of percutaneous transluminal coronary angioplasty(PTCA) include abrupt closure,which occurs in 2% to 10% of patients,and is associated with increased morbidity and mortality.Periprocedural myocardial infarction due to side branch occlusion or embolization occurs in 5% to 20% of patients.Patients with acute coronary syndromes,older age,and complex lesions are at greater risk of periprocedural complications.Technical advances,primarily stenting,are useful in the prevention and management of acute closure,but are also accompanied by thrombotic complications.It remains to be seen whether the new antithrombin agents reduce the rate of periprocedural complications if used in combination with aspirin and new antiplatelet therapies.These antiplatelet agents(ticlopidine,clopidogrel,abciximab,eptifibatide,and tirofiban) reduce the rate of ischemic complications and have become standard adjunctive therapy for patients who undergo PTCA.